Question explored with the scientific record
Conversation so far
- 1 does 20 mg of pravastatin help with general inflammation
- 2 what helps to reduce general inflammation
- 3 how much improvement in lipid scores should I expect from going from 10 mg pravastatin per day (for many years) to 20 mg/day?
Answered on this page ↓
how much improvement in lipid scores should I expect from going from 10 mg pravastatin per day (for many years) to 20 mg/day?
The short version: expect only a small extra drop, roughly a few more percent off LDL, and no proof it buys you anything you can feel.
Pravastatin is a weak statin, and doubling a low dose adds little. The best dose-response data here is from the STELLAR comparison, where pravastatin across its 10 to 40 mg range lowered LDL by 20 to 30% [3]. That is the whole span from 10 to 40 mg. Going from 10 to 20 mg sits inside that range, so the increment is a fraction of it, not a doubling of effect.
| Pravastatin dose | LDL reduction (STELLAR) |
|---|---|
| 10 mg | 20% |
| 40 mg | 30% |
The 10 mg arm in a separate trial cut LDL by 18% [1]. A 20 mg dose in diabetic patients moved LDL from 123 to 100 mg/dL over 12 weeks [4]. None of these isolate the 10-to-20 step, so the exact increment is not in front of me.
What you actually get from the extra 10 mg is a lab number, not a proven outcome. The hard-outcome trials used pravastatin at 40 mg, not 20 [2][5]. No record here shows that stepping 10 to 20 mg changes heart attacks or death. And the all-cause mortality benefit across statins is small: a meta-analysis found about 0.8% absolute reduction [5].
My call: the bump is modest and mostly cosmetic on your lipid panel; if your numbers are already near target, the extra milligram buys little. Confidence: moderate, because the dose-response is real but the 10-to-20 step itself was not directly tested here.
Sources used 5
-
Pitavastatin: Efficacy and Safety Profiles of A Novel Synthetic HMG‐CoA Reductase Inhibitor
Pitavastatin, a fully synthetic HMG-CoA reductase inhibitor, produces potent dose-dependent LDL cholesterol reduction in hypercholesterolemic patients and has pharmacokinetic properties suggesting fewer drug-drug interactions than other statins.
DOI: 10.1111/j.1527-3466.2003.tb00116.x -
Reduction in Recurrent Cardiovascular Events With Intensive Lipid-Lowering Statin Therapy Compared With Moderate Lipid-Lowering Statin Therapy After Acute Coronary Syndromes
An exploratory analysis of the PROVE IT-TIMI 22 trial showing that intensive lipid-lowering therapy with atorvastatin 80 mg after acute coronary syndrome reduces not only first but also total cardiovascular events compared with pravastatin 40 mg, highlighting the value of deeper…
DOI: 10.1016/j.jacc.2009.10.005 -
Rosuvastatin – A Highly Effective New 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor: Review of Clinical Trial Data at 10–40 mg Doses in Dyslipidemic Patients
This narrative review reports that rosuvastatin 10-40 mg reduces LDL cholesterol more than atorvastatin, simvastatin, and pravastatin, raises HDL cholesterol, improves other lipid measures, enables more patients to reach lipid goals, and is well tolerated in dyslipidemic patient…
DOI: 10.1159/000070669 -
Effects of pravastatin on lipid levels, in vitro oxidizability of non-HDL lipoproteins and microalbuminuria in IDDM patients
In 20 insulin-dependent diabetic patients with incipient nephropathy, pravastatin 20 mg daily for 12 weeks lowered total cholesterol, LDL cholesterol, and ApoB without affecting non-HDL lipoprotein oxidation, metabolic control, or urinary albumin excretion, while CPK levels incr…
DOI: 10.1016/0168-8227(95)01138-2 -
Statin Use and the Risk of All-cause Mortality
Statins reduced all-cause mortality in some trials, but a meta-analysis found only a 0.8% absolute reduction, leaving the effect uncertain and prompting calls for trials with all-cause mortality as the primary endpoint.
DOI: 10.3904/kjm.2023.98.1.4